Cystatin C deficiency in human atherosclerosis and aortic aneurysms

Journal of Clinical Investigation

Volumn 104, Issue 9, 1999, Pages 1191-1197

  Shi, Guo Ping ^a   Sukhova, Galina K ^a   Grubb, Anders ^b   Ducharme, Anique ^a   Rhode, Luis H ^a   Lee, Richard T ^a   Ridker, Paul M ^a   Libby, Peter ^a   Chapman, Harold A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN K; CATHEPSIN S; CYSTATIN C; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; CYTOKINE; TRANSFORMING GROWTH FACTOR BETA1;

ABDOMINAL AORTA ANEURYSM; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL DIAMETER; CELL STIMULATION; CONTROLLED STUDY; ECHOGRAPHY; ELASTOLYSIS; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; PATHOGENESIS; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

EID: 0032718590     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7709     Document Type: Article

References (51)

1. Davies, M.J. 1996. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 94:2913-2020.
2. Ghorpade, A., and Baxter, B.T. 1996. Biochemistry and molecular regulation of matrix macromolecules in abdominal aortic aneurysms. Ann. NY Acad. Sci. 800:138-150.
3. Newby, A.C., Southgate, K.M., and Davies, M. 1994. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res. Cardiol. 89(Suppl. 1):59-70.
4. Thompson, R.W., and Parks, W.C. 1996. Role of matrix metalloproteinases in abdominal aortic aneurysm. Ann. NY Acad. Sci. 800:157-174.
5. Carmeliet, P., et al. 1997. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet. 17:439-444.
6. Rao, S.K., Reddy, K.V., and Cohen, J.R. 1996. Role of serine proteases in aneurysm development. Ann. NY Acad. Sci. 800:131-137.
7. Shi, G.-P., Munger, J.S., Meara, J.P., Rich, D.H., and Chapman, H.A. 1992. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastolytic cysteine protease. J. Biol. Chem. 267:7258-7262.
8. Shi, G.-P., et al. 1995. Molecular cloning of human cathepsin O, a novel endopeptidase and homologue of rabbit OC2. FEBS Lett. 357:129-134.
9. Sukhova, G.K., Shi, G.-P., Simon, D.I., Chapman, H.A., and Libby, P. 1998. Expression of elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 102:576-583.
10. Reddy, V.Y., Zhang, Q.Y., and Weiss, S.J. 1995. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc. Natl. Acad. Sci. USA. 92:3849-3853.
11. Werb, Z., and Chin, J.R. 1998. Extracellular matrix remodeling during morphogenesis. Ann. NY Acad. Sci. 857:110-118.
12. Barrett, A.J., Davies, M.E., and Grubb, A. 1984. The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem. Biophys. Res. Commun. 120:631-636.
13. Merz, G.S., et al. 1997. Human cystatin C forms an inactive dimer during intracellular trafficking in transfected CHO cells. J. Cell. Physiol. 173:423-432.
14. Abrahamson, M., Islam, M.Q., Szpirer, J., Szpirer, C., and Levan, G. 1989. The human cystatin C gene (CST3), mutated in hereditary cystatin C amyloid angiopathy, is located on chromosome 20. Hum. Genet. 82:223-226.
15. Abrahamson, M., Barrett, A.J., Salvesen, G., and Grubb, A. 1986. Isolation of six cysteine proteinase inhibitors from human urine. J. Biol. Chem. 261:11282-11289.
16. Takeyabu, K., et al. 1998. Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Eur. Respir. J. 12:1033-1039.
17. Skaleric, U., Babnik, J., Curin, V., Lah, T., and Turk, V. 1998. Immunochemical quantitation of cysteine proteinase inhibitor cystatin C in inflamed human gingiva. Arch. Oral Biol. 34:301-305.
18. Shimode, K., Fujihara, S., Nakamura, M., Kobayashi, S., and Tsunematsu, T. 1991. Diagnosis of cerebral amyloid angiopathy by enzyme-linked immunosorbent assay of cystatin C in cerebral fluid. Stroke. 22:860-866.
19. Ishiguro, H., Ohkubo, I., Mizokami, M., Titani, K., and Sasaki, M. 1989. The use of monoclonal antibodies to define levels of cystatin C in normal human serum. Hybridoma. 8:303-313.
20. Jensson, O., et al. 1990. Cystatin C mutation causing amyloid angiopathy and brain hemorrhage. Biol. Chem. Hoppe Seyler. 371(Suppl.):229-232.
21. Chapman, H.A., Reilly, J.J., Yee, R., and Grubb, A. 1990. Identification of cystatin C, a cysteine proteinase inhibitor, as a major secretory product of human alveolar macrophages in vitro. Am. Rev. Respir. Dis. 141:698-705.
22. Warfel, A.H., Zucker-Franklin, D., Frangione, B., and Ghiso, J. 1987. Constitutive secretion of cystatin C (gamma-trace) by monocytes and macrophages and its downregulation after stimulation. J. Exp. Med. 166:1912-1917.
23. Grainger, D.J., et al. 1995. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat. Med. 1:74-79.
24. Banda, M.J., Werb, Z., and McKerrow, J.H. 1987. Elastin degradation. Methods Enzymol. 144:288-305.
25. Rohde, L.E., et al. 1998. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 18:1765-1770.
26. Rohde, L.E., et al. 1999. Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. Arterioscler. Thromb. Vasc. Biol. 19:1695-1699.
27. Kyhse-Andersen, J., et al. 1994. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin. Chem. 40:1921-1926.
28. Chapman, H.A., Jr., and Stone, O.L. 1984. Comparison of live human neutrophil and alveolar macrophage elastolyric activity in vitro. Relative resistance of macrophage elastolytic activity to serum and alveolar proteinase inhibitors. J. Clin. Invest. 74:1693-1700.
29. Olafsson, I. 1995. The human cystatin C gene promoter: functional analysis and identification of heterogeneous mRNA. Scand. J. Clin. Lab. Invest. 55:597-607.
30. Buisson, A., et al. 1998. Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor beta 1. FASEB J. 12:1683-1691.
31. Cao, H.J., Hogg, M.G., Martino, L.J., and Smith, T.J. 1995. Transforming growth factor-beta induces plasminogen activator inhibitor type-1 in cultured human orbital fibroblasts. Invest. Ophthalmol. Vis. Sci. 36:1411-1419.
32. Su, S., DiBattista, J.A., Sun, Y., Li, W.Q., and Zafarullah, M. 1998. Up-regulation of tissue inhibitor of metalloproteinases-3 gene expression by TGF-beta in articular chondrocytes is mediated by serine/threonine and tyrosine kinases. J. Cell. Biochem. 70:517-527.
33. Snider, G.L. 1992. Emphysema: the first two centuries - and beyond. A historical overview, with suggestions for future research: Part 2. Am. Rev. Respir. Dis. 146:1615-1622.
34. Tetley, T.D. 1993. New perspectives on basic mechanisms in lung disease. VI. Proteinase imbalance: its role in lung disease. Thorax. 48:560-565.
35. DeClerck, Y.A., et al. 1997. Proteases and protease inhibitors in tumor progression. Adv. Exp. Med. Biol. 425:89-97.
36. Calkins, C.C., and Sloane, B.F. 1995. Mammalian cysteine protease inhibitors: biochemical properties and possible roles in tumor progression. Biol. Chem. Hoppe Seyler. 376:71-80.
37. Allaire, E., Forough, R., Clowes, M., Starcher, B., and Clowes, A.W. 1998. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J. Clin. Invest. 102:1413-1420.
38. Fabunmi, R.P., Sukhova, G.K., Sugiyama, S., and Libby, P. 1998. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells, a potential protective mechanism in plaque stability. Circ. Res. 83:270-278.
39. Knox, J.B., Sukhova, G.K., Whittemore, A.D., and Libby, P. 1997. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation. 95:205-212.
40. Thompson, R.W., et al. 1995. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: an elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J. Clin. Invest. 96:318-326.
41. McMillan, W.D., et al. In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. Arterioscler. Thromb. Vasc. Biol. 15:1139-1144.
42. Hansson, G.K., Holm, J., and Jonasson, L. 1989. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol. 135:169-175.
43. Szekanecz, Z., Shah, M.R., Pearce, W.H., and Koch, A.E. 1994. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: the possible role for IL-6 and interferon-gamma in vascular inflammation. Agents Actions. 42:159-162.
44. Schonbeck, U., et al. 1997. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ. Res. 81:448-454.
45. Galis, Z.S., Muszynski, M., Sukhova, G.K., Simon-Morrissey, E., and Libby, P. 1995. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann. NY Acad. Sci. 748:501-507.
46. Libby, P., et al. 1996. Macrophages and atherosclerotic plaque stability. Curr. Opin. Lipidol. 7:330-335.
47. Pearce, W.H., and Koch, A.E. 1996. Cellular components and features of immune response in abdominal aortic aneurysms. Ann. NY Acad. Sci. 800:175-185.
48. Elmore, J.R., Keister, B.F., Franklin, D.P., Youkey, J.R., and Carey, D.J. 1998. Expression of matrix metalloproteinases and TIMPs in human abdominal aortic aneurysms. Ann. Vasc. Surg. 12:221-228.
49. Tamarina, N.A., McMillan, W.D., Shively, V.P., and Pearce, W.H. 1997. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery. 122:264-71, discussion 271-272.
50. Ridker, P.M., and Haughie, P. 1998. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J. Investig. Med. 46:391-395.
51. McCaffrey, T.A., et al. 1997. Genomic instability in the type II TGF-beta 1 receptor gene in atherosclerotic and restenotic vascular cells. J. Clin. Invest. 100:2182-2188.